Cytosorbents (CTSO) Free Cash Flow Growth (3y) (2013 - 2026)
Cytosorbents (CTSO) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.95 Bn | 176.66 Bn | 6.27 Bn | 6.28% |
| 2 | Stryker | 128.83 Bn | 125.95 Bn | 3.81 Bn | 9.63% |
| 3 | Medtronic | 108.81 Bn | 99.59 Bn | 6.41 Bn | 0.05% |
| 4 | Boston Scientific | 68.39 Bn | 66.94 Bn | 3.61 Bn | 29.36% |
| 5 | Edwards Lifesciences | 48.28 Bn | 44.60 Bn | 1.29 Bn | -27.72% |
| 6 | Dexcom | 28.39 Bn | 27.27 Bn | 750.30 Mn | 77.20% |
| 7 | GE HealthCare Technologies | 28.30 Bn | 26.01 Bn | 1.98 Bn | -29.89% |
| 8 | Smith & Nephew | 26.95 Bn | 26.37 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.32 Bn | 2.07 Bn | -0.27% |
| 10 | Cytosorbents | 21.97 Mn | 17.17 Mn | 6.13 Mn | 27.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.73% |
| Dec 31, 2025 | -212.13% |
| Sep 30, 2025 | 40.60% |
| Jun 30, 2025 | 41.08% |
| Mar 31, 2025 | 26.77% |
| Dec 31, 2024 | 38.41% |
| Sep 30, 2024 | 3.57% |
| Jun 30, 2024 | -19.43% |
| Mar 31, 2024 | -20.69% |
| Dec 31, 2023 | -78.57% |
| Sep 30, 2023 | -14.00% |
| Jun 30, 2023 | -78.98% |
| Mar 31, 2023 | 3.37% |
| Dec 31, 2022 | 26.84% |
| Sep 30, 2022 | -32.39% |
| Jun 30, 2022 | -31.46% |
| Mar 31, 2022 | -24.91% |
| Dec 31, 2021 | -46.86% |
| Sep 30, 2021 | -3.08% |
| Jun 30, 2021 | 7.06% |